Nancy Wysenski, EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 185,704 shares at $54.50 ($10.4M) on 2012-05-07, disclosed to the SEC on 2012-05-09.
Scheduled sale ($10.4M) by EVP, Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.50 | 147,695 | $8.0M | 77.3% |
| 2 | $59.19 | 9,063 | $536K | 5.2% |
| 3 | $62.08 | 10,196 | $633K | 6.1% |
| 4 | $63.52 | 18,750 | $1.2M | 11.4% |
| Total | $56.06 avg | 185,704 | $10.4M | 100% |
| Filing → |
| ALKS | BUY | 2019-03-18 | $270K | — | Filing → |
| VRTX | SELL | 2012-06-01 | $11.6M | — | Filing → |
| VRTX | SELL | 2012-01-23 | $224K | — | Filing → |